Maple Capital Management Inc. Purchases 493 Shares of AbbVie Inc. $ABBV

Maple Capital Management Inc. raised its position in AbbVie Inc. (NYSE:ABBV) by 14.4% in the second quarter, HoldingsChannel.com reports. The fund owned 3,922 shares of the company’s stock after purchasing an additional 493 shares during the quarter. Maple Capital Management Inc.’s holdings in AbbVie were worth $728,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of ABBV. Brighton Jones LLC increased its holdings in shares of AbbVie by 17.4% in the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after purchasing an additional 3,401 shares during the last quarter. Revolve Wealth Partners LLC boosted its holdings in shares of AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after buying an additional 3,064 shares during the period. Rice Hall James & Associates LLC boosted its holdings in shares of AbbVie by 9.3% during the 1st quarter. Rice Hall James & Associates LLC now owns 5,144 shares of the company’s stock worth $1,078,000 after buying an additional 437 shares during the period. Hohimer Wealth Management LLC grew its stake in AbbVie by 23.4% in the 1st quarter. Hohimer Wealth Management LLC now owns 1,895 shares of the company’s stock valued at $397,000 after buying an additional 359 shares during the last quarter. Finally, Apollon Financial LLC acquired a new position in shares of AbbVie in the first quarter valued at approximately $277,000. 70.23% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ABBV. Piper Sandler restated an “overweight” rating and set a $289.00 target price (up previously from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. Evercore ISI increased their price target on AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a research report on Monday, September 22nd. Raymond James Financial set a $256.00 price objective on AbbVie in a research note on Monday, November 3rd. Daiwa America upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 7th. Finally, HSBC set a $225.00 price target on AbbVie in a research report on Thursday, October 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $236.57.

AbbVie Price Performance

Shares of ABBV stock opened at $225.06 on Wednesday. The business has a fifty day simple moving average of $223.67 and a 200 day simple moving average of $203.22. The company has a market cap of $397.76 billion, a P/E ratio of 107.17, a P/E/G ratio of 1.42 and a beta of 0.50. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. AbbVie Inc. has a twelve month low of $163.81 and a twelve month high of $244.81.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The firm’s revenue was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, sell-side analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.1%. This is an increase from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio (DPR) is presently 524.24%.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.